肝素结合表皮生长因子作为癌症治疗靶点的研究进展  

Progress of Heparin-binding Epidermal Growth Factor as a Therapeutic Target in Cancer

作　　者：李慧[1] 汤小晗[1] 卢美松[1] 

机构地区：[1]哈尔滨医科大学附属第一医院妇产科,哈尔滨150001

出　　处：《医学综述》2015年第23期4283-4286,共4页Medical Recapitulate

摘　　要：表皮生长因子受体(EGFR/Erb B1)属于酪氨酸激酶家族,其中EGFR/Erb B1和Erb B2参与多种肿瘤细胞学行为。肝素结合表皮生长因子(HB-EGF)是表皮生长因子(EGF)家族中的成员,主要功能由可溶形式产生,参与多种生理病理过程。多项研究结果表明,HB-EGF在肿瘤组织中的表达量较正常组织增加,密切参与肿瘤细胞的形成、迁移、入侵、扩散和增殖的各项过程。以HB-EGF作为新型的癌症治疗靶点,抑制其促有丝分裂活性是一条改善癌症患者临床治疗效果的有效途径。Epidermal growth factor receptor （EGFR/ErbB1） belongs to tyrosine kinase family, EGFR/ ErbB1 and ErbB2 are involved in a variety of tumor cytological behaviors. Heparin-binding epidermal growth factor（HB-EGF） is the member of epidermal growth factor（EGF） family. The soluble form generates its main function,which participates in a variety of physiological and pathological processes. Lots of researches＇ results show that the HB-EGF expression levels in tumor tissue is significant increased. HB-EGF is closely involved in the formation, migration, invasion, metastasis, and proliferation of tumor cells. HB-EGF is a novel target for cancer therapy. Inhibiting the mitogenic activity of HB-EGF is an effective way to improve the clinical outcome for cancer patients.

关 键 词：肝素结合表皮生长因子 表皮生长因子受体 交叉反应物质197 肿瘤治疗方案 

分 类 号：R730.22[医药卫生—肿瘤]